keyword
MENU ▼
Read by QxMD icon Read
search

Symbicort

keyword
https://www.readbyqxmd.com/read/27817813/equivalent-bronchodilation-with-budesonide-formoterol-combination-via-easyhaler-and-turbuhaler-in-patients-with-asthma
#1
Satu Lähelmä, Mikko Vahteristo, Hristo Metev, Margarita Taseva, Nadezhda Stamatova, Anna Bartha, Judit Schlezák, Ulla Sairanen
BACKGROUND: Therapeutic equivalence of Budesonide/formoterol Easyhaler compared to Symbicort Turbuhaler has been previously demonstrated with in vitro and pharmacokinetic studies. This study was performed to confirm equivalent bronchodilator efficacy of the products in asthmatic patients. METHODS: A randomised, single-dose, 4-period crossover study was carried out in a double-blind, double-dummy manner in 11 study sites. The studied doses were 320/9 μg and 1280/36 μg of budesonide/formoterol delivered by Easyhaler and Turbuhaler...
November 2016: Respiratory Medicine
https://www.readbyqxmd.com/read/27635793/variability-in-delivered-dose-from-pressurized-metered-dose-inhaler-formulations-due-to-a-delay-between-shake-and-fire
#2
Ross H M Hatley, Jacob Parker, John N Pritchard, Dirk von Hollen
BACKGROUND: Pressurized metered-dose inhalers (pMDIs) should be shaken before use to prevent creaming or sedimentation of the drugs in solution; however, data published on this topic are limited, and it is rarely specified how soon after shaking the device should be actuated. Delays between shaking and firing the pMDI have previously been shown to cause significant inhomogeneity in delivered dose. We studied the effect of various shake-fire delays on the drug delivered from five commercially available pMDIs commonly prescribed for asthma and chronic obstructive pulmonary disease to assess the potential variability in delivered dose...
September 16, 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://www.readbyqxmd.com/read/27552906/numerical-simulation-of-emitted-particle-characteristics-and-airway-deposition-distribution-of-symbicort-%C3%A2-turbuhaler-%C3%A2-dry-powder-fixed-combination-aerosol-drug
#3
Árpád Farkas, Ágnes Jókay, Imre Balásházy, Péter Füri, Veronika Müller, Gábor Tomisa, Alpár Horváth
One of the most widespread dry powder fixed combinations used in asthma and chronic obstructive pulmonary disease (COPD) management is Symbicort(®) Turbuhaler(®). The aim of this study was to simulate the deposition distribution of both components of this drug within the airways based on realistic airflow measurements. Breathing parameters of 25 healthy adults (11 females and 14 males) were acquired while inhaling through Turbuhaler(®). Individual specific emitted doses and particle size distributions of Symbicort(®) Turbuhaler(®) were determined...
October 10, 2016: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/27540287/assessment-of-satisfaction-with-different-dry-powder-inhalation-devices-in-greek-patients-with-copd-and-asthma-the-anasa-study
#4
Eleftherios Zervas, Konstantinos Samitas, Mina Gaga
BACKGROUND: Poor adherence to inhaled therapy is common in patients with asthma and COPD. An inhaler selection based on patients' preference could be beneficial to adherence and treatment effectiveness. Properly designed questionnaires can assess patients' satisfaction with their medication devices. The aim of this study was to estimate, using the Feeling of Satisfaction with Inhaler (FSI-10) questionnaire, the ease of use and satisfaction of patients regarding three different marketed dry powder inhalers (DPIs): Diskus(®) (DK), Elpenhaler(®) (EH), and Turbuhaler(®) (TH)...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27070946/budesonide-formoterol-fumarate-dihydrate-for-the-treatment-of-asthma
#5
REVIEW
Ole D Wolthers
INTRODUCTION: One of the most widely used fixed combinations in asthma management is dry powder budesonide+formoterol fumarate dihydrate which is commercially available as Symbicort Turbuhaler(®) (and generic products), Easyhaler Bufomix(®) and DuoRespSpiromax(®) inhaler. The aim of this paper was to review the fixed dry powder combination of inhaled budesonide+formoterol fumarate dihydrate for asthma treatment in adolescents and adults. AREAS COVERED: A literature search using relevant search terms, reference lists for reviews and meta-analyses was performed...
2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/26850307/comparison-of-early-effects-of-budesonide-formoterol-maintenance-and-reliever-therapy-with-fluticasone-furoate-vilanterol-for-asthma-patients-requiring-step-up-from-inhaled-corticosteroid-monotherapy
#6
Soichiro Hozawa, Michikazu Terada, Yoshinori Haruta, Maki Hozawa
BACKGROUND: If asthma patients fail to achieve symptom control using a medium dose of inhaled corticosteroid (ICS) alone, addition of a long-acting β2 agonist (LABA) is the preferred treatment. Currently, there are several combinations of ICS/LABA that are available, each of which has a different property. Here, we aimed to compare the early effects of budesonide/formoterol (BUD/FM; Symbicort(®)) for maintenance and reliever therapy (SMART) with a fixed dose of fluticasone furoate/vilanterol (FF/VI; Relvar(®))...
April 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/26831844/real-life-effectiveness-of-budesonide-formoterol-therapy-in-asthma-a-subanalysis-of-the-smartasia-study
#7
Jiangtao Lin, Yan Tang, Qingyu Xiu, Jian Kang, Shaoxi Cai, Kewu Huang, Yohji Itoh, Xia Ling, Nanshan Zhong
BACKGROUND: In the Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia, the effectiveness of single-inhaler budesonide/formoterol maintenance and reliever therapy was evaluated in patients with poorly controlled asthma. OBJECTIVE: To study the effects of this therapy on a Chinese patient subgroup. METHODS: In this 12-week, multicenter, open-label therapeutic phase IV study, patients with partially controlled or uncontrolled asthma were switched from their usual asthma treatment to budesonide/formoterol (160/4...
January 2016: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/26629345/three-month-validation-of-a-turbuhaler-electronic-monitoring-device-implications-for-asthma-clinical-trial-use
#8
Janine Pilcher, Philippa Shirtcliffe, Mitesh Patel, Steve McKinstry, Terrianne Cripps, Mark Weatherall, Richard Beasley
BACKGROUND: Electronic monitoring of inhaled asthma therapy is suggested as the 'gold standard' for measuring patterns of medication use in clinical trials. The SmartTurbo (Adherium (NZ) Ltd, Auckland, New Zealand) is an electronic monitor for use with a turbuhaler device (AstraZeneca, UK). The aim of this study was to determine the accuracy of the SmartTurbo in recording Symbicort actuations over a 12-week period of use. METHODS: Twenty SmartTurbo monitors were attached to the base of 20 Symbicort turbuhalers...
2015: BMJ Open Respiratory Research
https://www.readbyqxmd.com/read/26355743/effect-of-flow-rate-on-in-vitro-aerodynamic-performance-of-nexthaler-%C3%A2-in-comparison-with-diskus-%C3%A2-and-turbohaler-%C3%A2-dry-powder-inhalers
#9
Francesca Buttini, Gaetano Brambilla, Diego Copelli, Viviana Sisti, Anna Giulia Balducci, Ruggero Bettini, Irene Pasquali
BACKGROUND: European and United States Pharmacopoeia compendial procedures for assessing the in vitro emitted dose and aerodynamic size distribution of a dry powder inhaler require that 4.0 L of air at a pressure drop of 4 kPa be drawn through the inhaler. However, the product performance should be investigated using conditions more representative of what is achievable by the patient population. This work compares the delivered dose and the drug deposition profile at different flow rates (30, 40, 60, and 90 L/min) of Foster NEXThaler(®) (beclomethasone dipropionate/formoterol fumarate), Seretide(®) Diskus(®) (fluticasone propionate/salmeterol xinafoate), and Symbicort(®) Turbohaler(®) (budesonide/formoterol fumarate)...
April 2016: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://www.readbyqxmd.com/read/26220014/can-extrafine-dry-powder-aerosols-improve-lung-deposition
#10
Anne H de Boer, Doetie Gjaltema, Paul Hagedoorn, Henderik W Frijlink
There is increasing interest in the use of so-called 'extrafine' aerosols to target the small airways in the management of asthma and COPD. Using previously presented deposition data, we assessed whether submicron (<1μm) particles can improve central and deep lung deposition. Our data show instead that particles in the range 1-3μm are much more relevant in this respect. Based on this finding the Symbicort Turbuhaler, Seretide Diskus, Rolenium Elpenhaler and Foster (Fostair) NEXThaler ICS/LABA combination DPIs were tested in vitro as a function of the pressure drop (2, 4 and 6kPa) across the inhaler...
October 2015: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/26201967/de-agglomeration-effect-of-the-us-pharmacopeia-and-alberta-throats-on-carrier-based-powders-in-commercial-inhalation-products
#11
Sharon Shui Yee Leung, Patricia Tang, Qi Tony Zhou, Zhenbo Tong, Cassandra Leung, Janwit Decharaksa, Runyu Yang, Hak-Kim Chan
The US pharmacopeia (USP) and Alberta throats were recently reported to cause further de-agglomeration of carrier-free powders emitted from some dry powder inhalers (DPIs). This study assessed if they have similar influences on commercially available carrier-based DPIs. A straight tube, a USP throat, and an Alberta throat (non-coated and coated) were used for cascade impaction testing. Aerosol fine particle fraction (FPF ≤ 5 μm) was computed to evaluate throat-induced de-agglomeration. Computational fluid dynamics are employed to simulate airflow patterns and particle trajectories inside the USP and Alberta throats...
November 2015: AAPS Journal
https://www.readbyqxmd.com/read/26042485/bioequivalence-of-budesonide-plus-formoterol-bf-spiromax%C3%A2-and-bf-turbohaler%C3%A2-with-and-without-charcoal-block-in-healthy-volunteers
#12
RANDOMIZED CONTROLLED TRIAL
Lori Weisfeld, Youyi Shu, Tushar P Shah
OBJECTIVE: Budesonide formoterol (BF) Spiromax® is a breath-actuated dry-powder inhaler designed to deliver similar combinations of budesonide and formoterol as Symbicort® Turbohaler®. We performed two studies to demonstrate pharmacokinetic (PK) equivalence of BF Spiromax with BF Turbohaler. MATERIALS AND METHODS: Two single-center, open-label, randomized, 5-period crossover studies were performed. The first study compared BF Spiromax 160/4.5 μg with BF Turbohaler 200/6 μg, while the second study compared BF Spiromax 320/9 μg with BF Turbohaler 400/12 μg...
July 2015: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/25879303/effect-of-direct-to-consumer-advertising-on-asthma-medication-sales-and-healthcare-use
#13
Matthew Daubresse, Susan Hutfless, Yoonsang Kim, Rachel Kornfield, Dima M Qato, Jidong Huang, Kay Miller, Sherry L Emery, G Caleb Alexander
RATIONALE: The United States is one of only two countries that permit direct-to-consumer advertising (DTCA) of prescription drugs, and many questions remain regarding its effects. OBJECTIVES: To quantify the association between asthma-related DTCA, pharmacy sales, and healthcare use. METHODS: This was an ecological study from 2005 through 2009 using linked data from Nielsen (DTCA television ratings), the IMS Health National Prescription Audit (pharmacy sales), and the MarketScan Commercial Claims data (healthcare use) for 75 designated market areas in the United States...
July 1, 2015: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/25757188/equivalent-lung-dose-and-systemic-exposure-of-budesonide-formoterol-combination-via-easyhaler-and-turbuhaler
#14
RANDOMIZED CONTROLLED TRIAL
Satu Lähelmä, Ulla Sairanen, Jussi Haikarainen, Jani Korhonen, Mikko Vahteristo, Rainard Fuhr, Merja Kirjavainen
BACKGROUND: Easyhaler(®) device-metered dry powder inhaler containing budesonide and formoterol fumarate dihydrate (hereafter formoterol) for the treatment of asthma and chronic obstructive pulmonary disease has been developed. The current approvals of the product in Europe were based on several pharmacokinetic (PK) bioequivalence (BE) studies, and in vitro-in vivo correlation (IVIVC) modeling. METHODS: Four PK studies were performed to compare the lung deposition and total systemic exposure of budesonide and formoterol after administration of budesonide/formoterol Easyhaler and the reference product, Symbicort Turbuhaler...
December 2015: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://www.readbyqxmd.com/read/25273642/-dynamic-characteristics-of-flow-trainer-for-dpi-and-its-clinical-relevance
#15
Tetsuri Kondo, Takanori Shimizu, Toshimori Tanigaki, Makoto Hibino, Motoki Ohe, Sakurako Tajiri
BACKGROUND: Trainer devices are widely employed for flow instruction in the use of dry powder inhalers (DPI). However, their aerodynamic characteristics in actual use have yet to be investigated. METHODS: We recorded inhalation flow signals and sounds produced from trainers for Diskus®, Symbicort®, Pulmicort® and Twisthaler® while five volunteers inhaled from the trainers with various inhalation patterns. RESULTS: Inhalation flow was classified into four patterns; the best, trapezoid, delayed peak and others...
September 2014: Arerugī, [Allergy]
https://www.readbyqxmd.com/read/25252183/performance-of-pressurized-metered-dose-inhalers-at-extreme-temperature-conditions
#16
COMPARATIVE STUDY
Chelsea M D Morin, James W Ivey, Jordan T F Titosky, Jonathan D Suderman, Jason S Olfert, Reinhard Vehring, Warren H Finlay
The performance of pressurized metered-dose inhalers (pMDIs) under a variety of temperature conditions was investigated. The effects of both inhaler temperature and ambient temperature were considered. The inhaler temperature ranged from -13.0°C to 41.7°C and the ambient temperature ranged from -12.0°C to 41.7°C. The in vitro lung dose was measured for four widely available pMDIs: Airomir(TM) , QVAR(TM) , Symbicort(®) , and Ventolin(®) . The in vitro lung dose through an Alberta Idealized Throat was measured by gravimetric assay, which was verified by UV spectroscopic assay...
November 2014: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/25166221/a-comparison-of-short-term-growth-during-treatment-with-two-dry-powder-combinations-of-inhaled-corticosteroids-and-long-acting-%C3%AE-%C3%A2-agonists
#17
RANDOMIZED CONTROLLED TRIAL
Ole D Wolthers, Tushar Shah
BACKGROUND: A combination of the inhaled corticosteroid budesonide and the long-acting β2-agonist formoterol has been formulated in a novel dry powder inhaler, Spiromax(®). The objective was to compare lower leg growth in children with asthma treated with inhaled budesonide+formoterol (BF) delivered from the Spiromax inhaler with BF from the Symbicort Turbohaler(®). METHODS: Prepubescent children with persistent asthma (n=75, aged 6-11 years) were included in a randomized, double-blind, double-dummy, placebo-controlled, three-way crossover study with active treatment and placebo periods of 2 weeks duration...
June 2015: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://www.readbyqxmd.com/read/25003728/satisfaction-level-and-asthma-control-among-malaysian-asthma-patients-on-symbicort-maintenance-and-reliever-therapy-smart-in-the-primary-care-setting-smartest-study
#18
MULTICENTER STUDY
Chong-Kin Liam, Yong-Kek Pang, Keong-Tiong Chua
OBJECTIVE: To evaluate Malaysian patients' satisfaction levels and asthma control with Symbicort SMART® in the primary care setting. METHOD: This is a cross-sectional, multicentre study involving adult patients with persistent asthma who were prescribed only Symbicort SMART in the preceding one month prior to recruitment. Patients' satisfaction with Symbicort SMART and asthma control were evaluated using the self-administered Satisfaction with Asthma Treatment Questionnaire (SATQ) and the Asthma Control Test (ACT)...
June 2014: Asian Pacific Journal of Allergy and Immunology
https://www.readbyqxmd.com/read/24978441/evaluation-of-in-vitro-and-in-vivo-flow-rate-dependency-of-budesonide-formoterol-easyhaler-%C3%A2
#19
COMPARATIVE STUDY
L Pekka Malmberg, Mark L Everard, Jussi Haikarainen, Satu Lähelmä
BACKGROUND: The Easyhaler(®) (EH) device-metered dry powder inhaler containing budesonide and formoterol is being developed for asthma and chronic obstructive pulmonary disease (COPD). As a part of product optimization, a series of in vitro and in vivo studies on flow rate dependency were carried out. METHODS: Inspiratory flow parameters via EH and Symbicort(®) Turbuhaler(®) (TH) inhalers were evaluated in 187 patients with asthma and COPD. The 10(th), 50(th), and 90(th) percentile flow rates achieved by patients were utilized to study in vitro flow rate dependency of budesonide/formoterol EH and Symbicort TH...
October 2014: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://www.readbyqxmd.com/read/24761394/comparing-clinical-efficacy-of-symbicort-versus-pulmicort-in-reducing-asthma-symptom-and-improving-its-control
#20
Mohammad Emami, Azadeh Tayebi, Mojgan Gharipour, Somayeh Farzamnia, Akbar Kargari Temyarti
BACKGROUND: Recently, higher efficacy of the combination of long-acting beta2-adrenoceptor agonist and inhaled corticosteroids on controlling asthma symptoms has been hypothesized. This study aimed to examine the clinical effects of the combination of Budesonide with formoterol (Symbicort) and Budesonide (Pulmicort) alone in persistent asthma. MATERIALS AND METHODS: In a randomized double-blinded clinical trial, 76 patients with definite diagnosis of moderate-to-severe asthma were randomized to receive Pulmicort 180 mcg/inhalation two puffs twice daily, or receive Symbicort 80/4...
2014: Advanced Biomedical Research
keyword
keyword
32626
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"